AR122516A1 - NEW IL-2 SEQUENCES AND THEIR USES - Google Patents

NEW IL-2 SEQUENCES AND THEIR USES

Info

Publication number
AR122516A1
AR122516A1 ARP210101511A ARP210101511A AR122516A1 AR 122516 A1 AR122516 A1 AR 122516A1 AR P210101511 A ARP210101511 A AR P210101511A AR P210101511 A ARP210101511 A AR P210101511A AR 122516 A1 AR122516 A1 AR 122516A1
Authority
AR
Argentina
Prior art keywords
seq
sequences
new
cys
sequence identity
Prior art date
Application number
ARP210101511A
Other languages
Spanish (es)
Inventor
Nina Gunnarsson
Matiss Maleckis
David B Rosen
Original Assignee
Ascendis Pharma Oncology Div A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma Oncology Div A/S filed Critical Ascendis Pharma Oncology Div A/S
Publication of AR122516A1 publication Critical patent/AR122516A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una secuencia de proteína IL-2 de la fórmula Ala - SEQ A - Cys* - SEQ B (1), en donde SEQ A tiene al menos un 94% de identidad de secuencia con la SEQ ID Nº 1; SEQ B tiene al menos un 94% de identidad de secuencia con la SEQ ID Nº 2; Ala es un residuo de alanina; y Cys* es un residuo de cisteína; a conjugados de estos y a sus usos en el tratamiento del cáncer.An IL-2 protein sequence of the formula Ala-SEQ A-Cys*-SEQ B(1), wherein SEQ A has at least 94% sequence identity to SEQ ID NO:1; SEQ B has at least 94% sequence identity to SEQ ID No. 2; Ala is an alanine residue; and Cys* is a cysteine residue; to conjugates of these and their uses in the treatment of cancer.

ARP210101511A 2020-06-03 2021-06-02 NEW IL-2 SEQUENCES AND THEIR USES AR122516A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP20177974 2020-06-03

Publications (1)

Publication Number Publication Date
AR122516A1 true AR122516A1 (en) 2022-09-14

Family

ID=70977396

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210101511A AR122516A1 (en) 2020-06-03 2021-06-02 NEW IL-2 SEQUENCES AND THEIR USES

Country Status (1)

Country Link
AR (1) AR122516A1 (en)

Similar Documents

Publication Publication Date Title
MX2022014082A (en) Il-2 sequences and uses thereof.
BR112020020085A8 (en) COMPOUND, PHARMACEUTICAL COMPOSITION, AND METHODS FOR INDUCING AN IMMUNE RESPONSE, FOR INDUCING STING-DEPENDENT TYPE I INTERFERON PRODUCTION, AND FOR TREAT A CELL PROLIFERATION DISORDER
DE3880739D1 (en) EXPRESSION OF HUMAN PROAPOLIPOPROTEIN A-1.
ES2145451T3 (en) DNA AND PROTEIN SEQUENCE OF CODES BREAST CANCER SPECIFIC TO BREASTS.
MX2020010075A (en) Lysin-antimicrobial peptide (amp) polypeptide constructs, lysins, isolated polynucleotides encoding same and uses thereof.
PE20120501A1 (en) L-ASPARAGINASE TREATED WITH PEG
CL2022002837A1 (en) Antibody-drug conjugates comprising sting agonists (divisional 202202711)
PE20231648A1 (en) HUMAN INTERLEUKIN 2 CONJUGATES BIASED TO THE INTERLEUKIN 2 b and c RECEPTOR DIMER AND CONJUGATED WITH A NON-PEPTIDE HYDROSOLUBLE POLYMER
CO2021017664A2 (en) peptides
AR114790A1 (en) HYDROCARBON PRODUCTION
BR112021025699A2 (en) Anti-mesothelin antibodies and immunoconjugates thereof
EA202190888A1 (en) PEPTIDE FOR COSMETIC APPLICATIONS
BR112022025633A2 (en) ADAS UNDERSTANDING BACTERIAL SECRETION SYSTEMS
CL2021000129A1 (en) Solubilized apyrases, methods and uses
AR122516A1 (en) NEW IL-2 SEQUENCES AND THEIR USES
DOP2020000045A (en) ANTI-EGFR DRUG-ANTIBODY CONJUGATES (ADC) AND THEIR USES
MX2020012103A (en) Improved fviii fusion protein and use thereof.
BR112022004032A2 (en) Mixotrophic probiotic compositions and uses thereof in the treatment of abdominal distention
MX2021004879A (en) Klk5 inhibitory peptide.
AR045000A1 (en) EIMERIA GENE AND PROTEIN, AND ITS USE
MX2023000734A (en) Recombinant vaccinia virus.
AR040521A1 (en) SYNTHETIC GEN CODIFYING THE STIMULATING FACTOR OF HUMAN GRANULOCIT COLONIES FOR EXPRESSION E. COLI
AR119862A1 (en) ENHANCED POLYPEPTIDES CAPABLE OF CONVERTING THE SUBSTRATE 3-KETO-DESOXINIVALENOL INTO 3-EPI-DESOXINIVALENOL
AR113982A1 (en) ANTAGONIST PEPTIDE OF INTERLEUKIN-15 ACTIVITY
AR117019A1 (en) INTERLEUQUIN 10 CONJUGATES AND USES THEREOF